Intellia Therapeutics Stock News

They point to trouble for investors counting on a rebound.

They point to trouble for investors counting on a rebound.

The only thing standing in the way is the clinical trials process, which takes time and patience.

Regeneron (REGN) gains 17% YTD on the back of Eylea, Dupixent and good pipeline progress.

ARKK ETF has found a way to generate some fresh capital for purchases. Seven names have been sold but don't appear in the daily e-mail. See more on ARKK here.

Certara, Inc. (CERT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increa

Plus Tess Vigeland, host of The Wall Street Journal podcast "As We Work," joins us for a chat.

The FDA has outlined new draft guidance on what should be submitted in a clinical trial application and potentially concerning safety issues to track the genome editing products. The guidance recommends at least 15 years of long-term follow-up after product administration, aligning with past gene editing advice. Most recently, Intellia Therapeutics Inc (NASDAQ: NTLA ) recently unveiled additional data from the Phase 1 trial for NTLA-2001 gene therapy in ATTR amyloidosis. The draft guidance points to several specific risks … Full story available on Benzinga.com

Intellia Therapeutics (NASDAQ: NTLA ) has outperformed the market over the past 5 years by 19.59% on an annualized basis. Buying $100 In NTLA: 5 years ago, an investor could have purchased 6.95 shares of Intellia Therapeutics at the time with $100. This investment … Full story available on Benzinga.com

Intellia's (NTLA) shares decline following the decision of the USPTO, invalidating the patents licensed by Intellia to develop CRISPR-based gene therapies.

Intellia's (NTLA) shares decline following the decision of the USPTO, invalidating the patents licensed by Intellia to develop CRISPR-based gene therapies.

Intellia's (NTLA) investigational gene-editing therapy, NTLA-5001, gets an Orphan Drug tag from the FDA for AML.

Intellia Therapeutics Inc''s (NASDAQ: NTLA ) CRISPR-powered T cell therapy has received an FDA orphan drug designation . The autologous T cell receptor therapy, dubbed NTLA-5001, is being evaluated in a Phase 1/2a trial in acute myeloid leukemia, the white blood cell cancer that affects blood and bone marrow. A … Full story available on Benzinga.com

NTLA-5001, a novel T cell receptor (TCR)-T cell therapy, is currently being evaluated in a Phase 1/2a study in adults with persistent or recurrent acute myeloid leukemia NTLA-5001, a novel T cell rece

NTLA-5001, a novel T cell receptor (TCR)-T cell therapy, is currently being evaluated in a Phase 1/2a study in adults with persistent or recurrent acute myeloid leukemia NTLA-5001, a novel T cell receptor (TCR)-T cell therapy, is currently being evaluated in a Phase 1/2a study in adults with persistent or recurrent acute myeloid leukemia